AMA0428, a novel and potent ROCK inhibitor, as a neuroprotective and regenerative therapy for glaucoma
-
1
KU Leuven, Biology, Belgium
-
2
Amakem Therapeutics, Belgium
Despite successful IOP lowering therapies, developing alternative treatment strategies is still necessary, to prevent/repair glaucomatous damage to the retina and optic nerve. Neuroprotective approaches are warranted to protect RGCs and halt further axonal degeneration. In addition, strategies that stimulate injured RGCs to regenerate are necessary to repair structural and functional connectivity. Here, the potential role of Rho-associated kinase (ROCK) inhibitors was elucidated by using both ex vivo and in vivo models. More in detail, AMA0428, a novel and potent ROCK inhibitor, developed by Amakem Therapeutics, was investigated in comparison to commercially available ROCK inhibitors. The ex vivo neuroprotective effect of ROCK inhibitors was evaluated by using adult mouse retinal explants. The potential neuroprotective effect of AMA0428 was also studied in vivo, using the optic nerve crush (ONC) model. Second, the regenerative potential of the ROCK inhibitors was investigated ex vivo on postnatal day 3 (P3) retinal explants. Finally, experiments are ongoing to assess the regeneration-promoting effect of AMA0428 in vivo. Adult explants, treated with AMA0428, showed enhanced RGC survival compared to vehicle-treated explants. In contrast, preliminary in vivo data indicated no neuroprotective potential of AMA0428. Administration of AMA0428 to P3 retinal explants showed a significant induction of neurite outgrowth. Strikingly, even when dosed ten times lower, AMA0428 was more potent than the reference ROCK inhibitors. Evaluation of AMA0428 via ex vivo approaches, suggests that this novel ROCK inhibitor holds very promising neuroprotective and regeneration potential. Additional in vivo experiments are currently being performed to confirm these exciting ex vivo results.
Keywords:
rho kinase,
axonal outgrowth,
retinal cell survival,
porcine retinal cell biology,
underlying mechanisms
Conference:
11th National Congress of the Belgian Society for Neuroscience, Mons, Belgium, 22 May - 22 May, 2015.
Presentation Type:
Poster presentation
Topic:
Neuroscience
Citation:
Lefevere
E,
Van Hove
I,
De Groef
L,
Sergeys
J,
Buyens
T,
Castermans
K,
Kindt
N and
Moons
L
(2015). AMA0428, a novel and potent ROCK inhibitor, as a neuroprotective and regenerative therapy for glaucoma.
Front. Neurosci.
Conference Abstract:
11th National Congress of the Belgian Society for Neuroscience.
doi: 10.3389/conf.fnins.2015.89.00028
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
30 Apr 2015;
Published Online:
05 May 2015.
*
Correspondence:
Miss. Evy Lefevere, KU Leuven, Biology, Leuven, Vlaams-Brabant, 3000, Belgium, evy.lefevere@bio.kuleuven.be